Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more. Published ...
MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Stockhead on MSN
Alterity delivers encouraging phase II data in MSA trial
Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an oral presentation at the American Autonomic Society (AAS) 36th International ...
- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
DelveInsight's“ Multiple System Atrophy Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback